With key results expected from its lead cancer program this year, the cancer drug specialist Tesaro has stocked its coffers with $91.2 million from a public stock offering.
After taking a beating in previous years, biotech has been hot sector on Wall Street this year. The Nasdaq Biotech Index has shot up 30% this year compared with 15% growth in the broader market. And the fact that this year's total number of biotech IPOs already matches that of 2011 indicates that there could be a growing appetite for these types of investments. But there's no indication that we're on the verge of, or will ever, return to the go-go years of the 1990s when biotechs more easily went public at lofty values. Here's the full report >>
GlobeImmune is hoping to ride the new wave of enthusiasm over immunotherapies to a successful IPO designed to raise up to $69 million.
Just two years after getting started, the experienced cancer pros at Tesaro have pulled off a successful IPO.
Tesaro is betting that its management's rep and a late-stage program will help entice investors to snap up 6 million shares at $12 to $15 a share, worth an estimated $86.3 million.
The therapy fits into a new class of cancer drugs called PARP inhibitors, with potential to treat ovarian and breast cancers.
Kleiner Perkins Caulfield & Byers has closed the books on a new $525 million fund. And a chunk of that treasure is earmarked for early-stage life science companies.
Tesaro has put together an SEC filing that makes one essential promise to prospective investors: This company is built for speed.
The veteran crew of cancer drug developers at MGI Pharma who went on to found Tesaro a little more than a year ago have rounded up a whopping $101 million B round led by Kleiner Perkins Caufield
A group of MGI Pharma alumni is launching a Boston-based startup named Tesaro in Boston with $60 million in venture backing for its plan to acquire, develop and commercialize new cancer drugs. The